PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
PTC Therapeutics (PTCT) PT Lowered to $46 at RBC Capital
November 6, 2018 6:46 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $51.00) while maintaining an Outperform rating.
"3Q optics were unfavorable, given the Translarna miss, Emflaza guidance adjustment, and increased spend, and we could see shares trade off modestly," Abrahams commented.
... MorePTC Therapeutics (PTCT) Misses Q3 EPS by 66c, Revenues Miss; Lowers FY18 Revenue Outlook
November 5, 2018 4:38 PM ESTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.06), $0.66 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $53.59 million versus the consensus estimate of $70.9 million.
"We have been aggressively pursuing our vision to build a leading, fully integrated,... More
